Keros Therapeutics Key Executives
This section highlights Keros Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Keros Therapeutics
(Showing 0 of )
Keros Therapeutics Earnings
This section highlights Keros Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
$14.21
Stock Price
$576.39M
Market Cap
169
Employees
Lexington, MA
Location
Financial Statements
Access annual & quarterly financial statements for Keros Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $3.55M | $151.00K | $- | $20.10M | $- |
| Cost of Revenue | $- | $815.00K | $1.61M | $898.00K | $605.00K |
| Gross Profit | $3.55M | $-664.00K | $-1.61M | $19.20M | $-605.00K |
| Gross Profit Ratio | 100.00% | -439.74% | - | 95.53% | - |
| Research and Development Expenses | $173.63M | $135.26M | $87.27M | $55.14M | $33.86M |
| General and Administrative Expenses | $40.75M | $34.83M | $27.52M | $21.33M | $12.80M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $40.75M | $34.83M | $27.52M | $21.33M | $12.80M |
| Other Expenses | $- | $- | $-7.08M | $-356.00K | $-2.46M |
| Operating Expenses | $214.38M | $170.09M | $107.71M | $76.47M | $44.20M |
| Cost and Expenses | $214.38M | $170.09M | $107.71M | $76.47M | $44.20M |
| Interest Income | $- | $- | $1.00K | $4.00K | $6.00K |
| Interest Expense | $- | $- | $1.00K | $4.00K | $6.00K |
| Depreciation and Amortization | $1.23M | $815.00K | $1.61M | $898.00K | $605.00K |
| EBITDA | $-185.82M | $-152.18M | $-103.06M | $-56.37M | $-44.92M |
| EBITDA Ratio | -5234.48% | -100779.47% | - | -280.46% | - |
| Operating Income | $-210.83M | $-169.94M | $-114.79M | $-56.37M | $-46.66M |
| Operating Income Ratio | -5938.96% | -112543.71% | - | -280.46% | - |
| Total Other Income Expenses Net | $23.78M | $16.95M | $10.11M | $-360.00K | $1.12M |
| Income Before Tax | $-187.05M | $-152.99M | $-104.68M | $-56.73M | $-45.53M |
| Income Before Tax Ratio | -5269.10% | -101319.21% | - | -282.25% | - |
| Income Tax Expense | $300.00K | $- | $1.00K | $2.01M | $-172.00K |
| Net Income | $-187.35M | $-152.99M | $-104.68M | $-58.74M | $-45.36M |
| Net Income Ratio | -5277.55% | -101319.21% | - | -292.26% | - |
| EPS | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 |
| EPS Diluted | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 |
| Weighted Average Shares Outstanding | 37.44M | 29.45M | 25.24M | 23.33M | 15.51M |
| Weighted Average Shares Outstanding Diluted | 37.44M | 29.45M | 25.24M | 23.33M | 15.51M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04M | $388.00K | $37.00K | $83.00K | $143.00K | $8.00K | $- | $- | $- | $- | $100.00K | $- | $20.00M | $- | $100.00K | $- | $- | $2.50M | $2.50M | $2.50M |
| Cost of Revenue | $- | $- | $306.00K | $277.00K | $247.00K | $551.00K | $545.00K | $689.00K | $448.00K | $337.00K | $514.00K | $316.00K | $302.00K | $223.00K | $9.98M | $179.00K | $9.67M | $8.39M | $7.26M | $8.53M |
| Gross Profit | $3.04M | $388.00K | $-269.00K | $-194.00K | $-104.00K | $-543.00K | $-545.00K | $-689.00K | $-448.00K | $-337.00K | $-414.00K | $-316.00K | $19.70M | $-223.00K | $-9.88M | $-179.00K | $-9.67M | $-5.89M | $-4.76M | $-6.03M |
| Gross Profit Ratio | 100.00% | 100.00% | -727.03% | -233.73% | -72.73% | -6787.50% | - | - | - | - | -414.00% | - | 98.49% | - | -9883.00% | - | - | -235.80% | -190.56% | -241.08% |
| Research and Development Expenses | $45.63M | $49.23M | $40.52M | $38.26M | $37.49M | $34.14M | $32.53M | $31.09M | $24.87M | $21.04M | $23.28M | $18.08M | $18.83M | $14.83M | $9.98M | $11.49M | $9.67M | $8.39M | $7.26M | $8.53M |
| General and Administrative Expenses | $10.66M | $9.82M | $9.96M | $10.31M | $9.11M | $9.15M | $8.80M | $7.78M | $7.09M | $6.94M | $7.45M | $6.05M | $6.03M | $5.37M | $5.66M | $4.27M | $3.62M | $3.55M | $3.65M | $1.98M |
| Selling and Marketing Expenses | $- | $- | $-306.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $10.66M | $9.82M | $9.65M | $10.31M | $9.11M | $9.15M | $8.80M | $7.78M | $7.09M | $6.94M | $7.45M | $6.05M | $6.03M | $5.37M | $5.66M | $4.27M | $3.62M | $3.55M | $3.65M | $1.98M |
| Other Expenses | $- | $- | $-196.00K | $-437.00K | $-10.94M | $3.84M | $3.83M | $3.06M | $2.24M | $-3.71M | $-3.38M | $-59.00K | $-74.00K | $-137.00K | $-80.00K | $-65.00K | $156.00K | $-86.00K | $158.00K | $-1.56M |
| Operating Expenses | $56.30M | $59.05M | $50.17M | $48.57M | $44.20M | $43.29M | $41.34M | $38.87M | $31.96M | $24.27M | $27.35M | $24.13M | $24.87M | $20.20M | $15.64M | $15.77M | $10.83M | $11.95M | $10.91M | $10.50M |
| Cost and Expenses | $56.30M | $59.05M | $50.48M | $48.57M | $44.20M | $43.29M | $41.34M | $38.87M | $31.96M | $24.27M | $27.35M | $24.13M | $24.87M | $20.20M | $15.64M | $15.77M | $10.83M | $11.95M | $10.91M | $10.50M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $2.00K | $1.00K | $2.00K |
| Depreciation and Amortization | $332.00K | $- | $306.00K | $277.00K | $247.00K | $551.00K | $545.00K | $689.00K | $448.00K | $337.00K | $514.00K | $316.00K | $302.00K | $223.00K | $194.00K | $179.00K | $75.00K | $72.00K | $68.00K | $63.00K |
| EBITDA | $-29.14M | $-58.66M | $-50.13M | $-48.21M | $-40.00M | $-43.07M | $-41.15M | $-38.87M | $-29.27M | $-20.20M | $-30.13M | $-24.07M | $-4.64M | $-20.20M | $-15.43M | $-15.77M | $-10.50M | $-11.91M | $-10.60M | $-11.91M |
| EBITDA Ratio | -957.99% | -15117.78% | -135494.59% | -58079.52% | -27969.23% | -538375.00% | - | - | - | - | -30128.00% | - | -23.20% | - | -15428.00% | - | - | -476.52% | -423.88% | -476.40% |
| Operating Income | $-53.25M | $-58.66M | $-50.44M | $-48.48M | $-46.45M | $-43.28M | $-41.34M | $-38.87M | $-31.96M | $-27.98M | $-30.73M | $-24.13M | $-4.87M | $-20.20M | $-15.54M | $-15.77M | $-13.29M | $-11.95M | $-10.91M | $-10.50M |
| Operating Income Ratio | -1750.62% | -15117.78% | -136321.62% | -58413.25% | -32486.01% | -541000.00% | - | - | - | - | -30728.00% | - | -24.34% | - | -15541.00% | - | - | -477.92% | -436.56% | -420.16% |
| Total Other Income Expenses Net | $7.53M | $5.70M | $5.18M | $5.37M | $6.21M | $3.84M | $3.83M | $3.06M | $2.24M | $4.47M | $3.46M | $-60.00K | $-75.00K | $-138.00K | $-81.00K | $-66.00K | $2.62M | $-88.00K | $157.00K | $-1.56M |
| Income Before Tax | $-45.73M | $-52.96M | $-45.26M | $-43.11M | $-40.24M | $-39.44M | $-37.51M | $-35.80M | $-29.72M | $-23.51M | $-27.27M | $-24.19M | $-4.94M | $-20.34M | $-15.62M | $-15.84M | $-10.68M | $-12.04M | $-10.76M | $-12.06M |
| Income Before Tax Ratio | -1503.16% | -13648.45% | -122316.22% | -51944.58% | -28141.96% | -493000.00% | - | - | - | - | -27266.00% | - | -24.71% | - | -15622.00% | - | - | -481.44% | -430.28% | -482.56% |
| Income Tax Expense | $300.00K | $- | $- | $-277.00K | $3.81M | $-210.00K | $3.83M | $-3.06M | $2.00K | $-4.47M | $-3.46M | $1.00K | $2.00M | $-38.00K | $-79.00K | $50.00K | $82.00K | $-156.00K | $1.00K | $-172.00K |
| Net Income | $-46.03M | $-52.96M | $-45.26M | $-43.11M | $-40.24M | $-39.44M | $-37.51M | $-32.74M | $-29.72M | $-19.04M | $-23.80M | $-24.19M | $-6.94M | $-20.30M | $-15.62M | $-15.88M | $-10.68M | $-12.04M | $-10.76M | $-11.89M |
| Net Income Ratio | -1513.02% | -13648.45% | -122316.22% | -51944.58% | -28141.96% | -493000.00% | - | - | - | - | -23804.00% | - | -34.70% | - | -15622.00% | - | - | -481.44% | -430.28% | -475.68% |
| EPS | $-1.14 | $-1.47 | $-1.25 | $-1.46 | $-1.34 | $-1.33 | $-1.27 | $-1.15 | $-1.09 | $-0.75 | $-0.99 | $-1.01 | $-0.30 | $-0.87 | $-0.67 | $-0.68 | $-0.49 | $-0.60 | $-0.61 | $-0.65 |
| EPS Diluted | $-1.14 | $-1.47 | $-1.25 | $-1.46 | $-1.34 | $-1.33 | $-1.27 | $-1.15 | $-1.09 | $-0.75 | $-0.99 | $-1.01 | $-0.30 | $-0.87 | $-0.67 | $-0.68 | $-0.49 | $-0.60 | $-0.61 | $-0.65 |
| Weighted Average Shares Outstanding | 40.34M | 36.10M | 36.10M | 29.45M | 30.13M | 29.67M | 29.60M | 28.37M | 27.33M | 25.55M | 24.05M | 23.99M | 23.44M | 23.36M | 23.31M | 23.23M | 21.62M | 20.18M | 17.62M | 18.19M |
| Weighted Average Shares Outstanding Diluted | 40.34M | 36.10M | 36.10M | 29.45M | 30.13M | 29.67M | 29.60M | 28.37M | 27.33M | 25.55M | 24.05M | 23.99M | 23.44M | 23.36M | 23.31M | 23.23M | 21.62M | 20.18M | 17.62M | 18.19M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $559.93M | $331.15M | $279.05M | $230.04M | $265.88M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $559.93M | $331.15M | $279.05M | $230.04M | $265.88M |
| Net Receivables | $4.46M | $1.09M | $841.00K | $18.00M | $216.00K |
| Inventory | $- | $- | $-841.00K | $3.06M | $1.47M |
| Other Current Assets | $26.22M | $15.05M | $5.88M | $3.20M | $1.63M |
| Total Current Assets | $588.89M | $347.29M | $285.77M | $251.44M | $267.73M |
| Property Plant Equipment Net | $23.49M | $19.47M | $17.57M | $2.40M | $1.60M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $1.21M | $1.33M | $1.33M | $115.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.50M | $2.05M | $2.12M | $82.00K | $- |
| Total Non-Current Assets | $26.99M | $22.73M | $21.01M | $3.81M | $1.72M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $615.89M | $370.02M | $306.78M | $255.25M | $269.44M |
| Account Payables | $4.60M | $5.45M | $3.34M | $3.65M | $2.15M |
| Short Term Debt | $1.98M | $1.00M | $910.00K | $1.72M | $846.00K |
| Tax Payables | $- | $- | $50.00K | $110.00K | $185.00K |
| Deferred Revenue | $- | $- | $- | $7.13M | $4.39M |
| Other Current Liabilities | $20.87M | $17.92M | $12.25M | $6.37M | $4.00M |
| Total Current Liabilities | $27.45M | $24.37M | $16.55M | $11.85M | $7.18M |
| Long Term Debt | $16.88M | $13.44M | $25.62M | $462.00K | $952.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $-12.81M | $-231.00K | $-414.00K |
| Total Non-Current Liabilities | $16.88M | $13.44M | $12.81M | $231.00K | $538.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $44.33M | $37.81M | $29.36M | $12.08M | $7.72M |
| Preferred Stock | $- | $- | $- | $0 | $269.44M |
| Common Stock | $4.00K | $3.00K | $2.00K | $2.00K | $2.00K |
| Retained Earnings | $-568.78M | $-381.43M | $-228.43M | $-123.75M | $-65.01M |
| Accumulated Other Comprehensive Income Loss | $- | $0 | $-0 | $-0 | $-269.44M |
| Other Total Stockholders Equity | $1.14B | $713.64M | $505.86M | $366.93M | $596.17M |
| Total Stockholders Equity | $571.55M | $332.21M | $277.42M | $243.17M | $261.72M |
| Total Equity | $571.55M | $332.21M | $277.42M | $243.17M | $261.72M |
| Total Liabilities and Stockholders Equity | $615.89M | $370.02M | $306.78M | $255.25M | $269.44M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $615.89M | $370.02M | $306.78M | $255.25M | $269.44M |
| Total Investments | $- | $1.21M | $1.33M | $1.33M | $115.00K |
| Total Debt | $18.86M | $14.44M | $13.27M | $1.09M | $899.00K |
| Net Debt | $-541.07M | $-316.70M | $-265.78M | $-228.95M | $-264.98M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $559.93M | $530.68M | $405.86M | $442.44M | $331.15M | $287.89M | $322.03M | $351.43M | $279.05M | $239.43M | $215.62M | $228.59M | $230.04M | $221.35M | $237.11M | $255.20M | $265.88M | $133.81M | $144.69M | $54.52M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $559.93M | $530.68M | $405.86M | $442.44M | $331.15M | $287.89M | $322.03M | $351.43M | $279.05M | $239.43M | $215.62M | $228.59M | $230.04M | $221.35M | $237.11M | $255.20M | $265.88M | $133.81M | $144.69M | $54.52M |
| Net Receivables | $4.46M | $1.92M | $1.34M | $1.78M | $1.09M | $898.00K | $964.00K | $1.15M | $841.00K | $146.00K | $146.00K | $167.00K | $18.00M | $169.00K | $245.00K | $- | $216.00K | $172.00K | $238.00K | $977.00K |
| Inventory | $- | $- | $1 | $1 | $14.05M | $15.32M | $10.94M | $9.13M | $-841.00K | $5.56M | $6.12M | $2.22M | $3.06M | $4.24M | $3.77M | $- | $1.47M | $2.30M | $3.31M | $2.61M |
| Other Current Assets | $24.51M | $19.44M | $25.51M | $18.91M | $15.05M | $15.64M | $11.32M | $9.65M | $5.88M | $6.30M | $6.59M | $2.47M | $3.20M | $4.56M | $4.06M | $779.00K | $1.63M | $2.43M | $3.59M | $2.95M |
| Total Current Assets | $588.89M | $552.05M | $432.71M | $463.13M | $347.29M | $304.44M | $334.31M | $362.22M | $285.77M | $245.88M | $222.36M | $231.22M | $251.44M | $226.07M | $241.42M | $255.98M | $267.73M | $136.42M | $148.52M | $58.54M |
| Property Plant Equipment Net | $23.49M | $24.19M | $18.94M | $19.43M | $19.47M | $19.03M | $19.10M | $19.30M | $17.57M | $2.13M | $2.31M | $2.32M | $2.40M | $2.56M | $1.93M | $1.63M | $1.60M | $1.72M | $1.81M | $1.94M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.21M | $1.21M | $1.21M | $1.21M | $1.33M | $1.33M | $1.33M | $1.33M | $1.33M | $1.33M | $1.33M | $1.33M | $115.00K | $115.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.50M | $3.04M | $2.15M | $2.05M | $2.05M | $1.57M | $1.57M | $1.59M | $2.12M | $3.22M | $667.00K | $275.00K | $82.00K | $- | $- | $- | $115.00K | $115.00K | $115.00K | $115.00K |
| Total Non-Current Assets | $26.99M | $27.23M | $22.31M | $22.69M | $22.73M | $21.81M | $22.00M | $22.21M | $21.01M | $6.67M | $4.30M | $3.92M | $3.81M | $3.89M | $2.04M | $1.75M | $1.72M | $1.83M | $1.92M | $2.05M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $615.89M | $579.27M | $455.02M | $485.82M | $370.02M | $326.25M | $356.31M | $384.44M | $306.78M | $252.55M | $226.66M | $235.14M | $255.25M | $229.96M | $243.46M | $257.73M | $269.44M | $138.25M | $150.44M | $60.59M |
| Account Payables | $4.60M | $4.98M | $6.54M | $4.99M | $5.45M | $3.87M | $4.15M | $4.68M | $3.34M | $2.65M | $7.66M | $3.06M | $3.65M | $2.81M | $1.37M | $3.01M | $2.15M | $1.72M | $4.85M | $2.43M |
| Short Term Debt | $1.98M | $1.86M | $2.19M | $2.10M | $1.00M | $1.22M | $- | $- | $455.00K | $910.00K | $1.34M | $1.77M | $862.00K | $1.69M | $898.00K | $872.00K | $423.00K | $824.00K | $800.00K | $776.00K |
| Tax Payables | $- | $- | $- | $- | $- | $30.00K | $20.00K | $50.00K | $50.00K | $37.00K | $48.00K | $90.00K | $110.00K | $83.00K | $106.00K | $140.00K | $185.00K | $- | $- | $43.00K |
| Deferred Revenue | $- | $- | $- | $-1.05M | $17.25M | $11.82M | $- | $- | $- | $- | $- | $- | $7.13M | $7.16M | $5.04M | $5.30M | $4.39M | $4.26M | $2.62M | $5.80M |
| Other Current Liabilities | $20.87M | $22.17M | $12.52M | $11.63M | $17.92M | $11.58M | $11.93M | $10.73M | $12.70M | $7.92M | $6.41M | $6.73M | $7.23M | $6.43M | $5.16M | $4.93M | $4.43M | $4.29M | $2.64M | $5.59M |
| Total Current Liabilities | $27.45M | $29.01M | $21.25M | $18.72M | $24.37M | $16.70M | $16.09M | $15.46M | $16.55M | $11.53M | $15.45M | $11.65M | $11.85M | $11.02M | $7.53M | $8.95M | $7.18M | $6.83M | $8.29M | $8.84M |
| Long Term Debt | $16.88M | $17.43M | $25.72M | $26.31M | $13.44M | $27.41M | $27.90M | $27.99M | $12.81M | $- | $- | $- | $231.00K | $906.00K | $484.00K | $722.00K | $476.00K | $1.17M | $1.38M | $1.59M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $-12.86M | $-13.15M | $- | $-13.70M | $-13.95M | $-13.99M | $- | $- | $- | $- | $- | $-437.00K | $-210.00K | $-314.00K | $62.00K | $-509.00K | $-601.00K | $-693.00K |
| Total Non-Current Liabilities | $16.88M | $17.43M | $12.86M | $13.15M | $13.44M | $13.70M | $13.95M | $13.99M | $12.81M | $455.00K | $670.00K | $3.95M | $231.00K | $469.00K | $274.00K | $408.00K | $538.00K | $663.00K | $783.00K | $901.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-455.00K | $-670.00K | $-3.95M | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $44.33M | $46.44M | $34.11M | $31.87M | $37.81M | $30.41M | $30.05M | $29.45M | $29.36M | $11.53M | $15.45M | $11.65M | $12.08M | $11.48M | $7.80M | $9.36M | $7.72M | $7.49M | $9.08M | $9.74M |
| Preferred Stock | $- | $- | $- | $- | $- | $0 | $- | $0 | $- | $- | $0 | $- | $0 | $- | $0 | $- | $0 | $138.25M | $150.44M | $75.72M |
| Common Stock | $4.00K | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $1.00K |
| Retained Earnings | $-568.78M | $-522.75M | $-469.80M | $-424.54M | $-381.43M | $-341.18M | $-301.74M | $-264.24M | $-228.43M | $-198.72M | $-175.21M | $-147.94M | $-123.75M | $-116.81M | $-96.52M | $-80.90M | $-65.01M | $-54.34M | $-42.30M | $-31.54M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $0 | $-0 | $- | $-0 | $-0 | $0 | $-0 | $- | $-0 | $- | $-0 | $-0 | $-0 | $-138.25M | $-150.44M | $- |
| Other Total Stockholders Equity | $1.14B | $1.06B | $890.71M | $878.48M | $713.64M | $637.02M | $628.00M | $619.22M | $505.86M | $439.74M | $386.41M | $371.43M | $- | $335.29M | $332.17M | $329.27M | $326.73M | $323.34M | $334.10M | $6.67M |
| Total Stockholders Equity | $571.55M | $532.84M | $420.92M | $453.95M | $332.21M | $295.84M | $326.26M | $354.98M | $277.42M | $241.03M | $211.21M | $223.49M | $243.17M | $218.48M | $235.66M | $248.37M | $261.72M | $130.76M | $141.36M | $50.85M |
| Total Equity | $571.55M | $532.84M | $420.92M | $453.95M | $332.21M | $295.84M | $326.26M | $354.98M | $277.42M | $241.03M | $211.21M | $223.49M | $243.17M | $218.48M | $235.66M | $248.37M | $261.72M | $130.76M | $141.36M | $50.85M |
| Total Liabilities and Stockholders Equity | $615.89M | $579.27M | $455.02M | $485.82M | $370.02M | $326.25M | $356.31M | $384.44M | $306.78M | $252.55M | $226.66M | $235.14M | $255.25M | $229.96M | $243.46M | $257.73M | $269.44M | $138.25M | $150.44M | $60.59M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $615.89M | $579.27M | $455.02M | $485.82M | $370.02M | $326.25M | $356.31M | $384.44M | $306.78M | $252.55M | $226.66M | $235.14M | $255.25M | $229.96M | $243.46M | $257.73M | $269.44M | $138.25M | $150.44M | $60.59M |
| Total Investments | $- | $- | $1.21M | $1.21M | $1.21M | $1.21M | $1.33M | $1.33M | $1.33M | $1.33M | $1.33M | $1.33M | $1.33M | $1.33M | $115.00K | $115.00K | $- | $- | $- | $- |
| Total Debt | $18.86M | $19.29M | $13.96M | $14.20M | $14.44M | $14.31M | $13.95M | $13.99M | $13.27M | $455.00K | $670.00K | $884.00K | $1.09M | $1.30M | $691.00K | $797.00K | $899.00K | $998.00K | $1.09M | $1.19M |
| Net Debt | $-541.07M | $-511.40M | $-391.91M | $-428.24M | $-316.70M | $-273.58M | $-308.07M | $-337.44M | $-265.78M | $-238.97M | $-214.95M | $-227.70M | $-228.95M | $-220.05M | $-236.42M | $-254.41M | $-264.98M | $-132.81M | $-143.59M | $-53.33M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-187.35M | $-152.99M | $-104.68M | $-58.74M | $-45.36M |
| Depreciation and Amortization | $1.23M | $815.00K | $674.00K | $378.00K | $278.00K |
| Deferred Income Tax | $- | $- | $- | $46.00K | $- |
| Stock Based Compensation | $34.87M | $28.76M | $18.68M | $11.72M | $4.10M |
| Change in Working Capital | $-11.44M | $-2.65M | $14.31M | $-16.07M | $2.27M |
| Accounts Receivables | $-2.60M | $-143.00K | $18.00M | $-18.00M | $922.00K |
| Inventory | $- | $-4.50M | $- | $1.04M | $-922.00K |
| Accounts Payables | $-249.00K | $1.61M | $-408.00K | $1.49M | $61.00K |
| Other Working Capital | $-8.59M | $384.00K | $-3.28M | $-597.00K | $2.21M |
| Other Non Cash Items | $1.82M | $1.56M | $953.00K | $520.00K | $1.82M |
| Net Cash Provided by Operating Activities | $-160.87M | $-124.51M | $-70.06M | $-62.15M | $-36.89M |
| Investments in Property Plant and Equipment | $-1.93M | $-2.46M | $-1.24M | $-1.02M | $-294.00K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-1.93M | $-2.46M | $-1.24M | $-1.02M | $-294.00K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $380.13M | $175.82M | $119.58M | $28.17M | $243.20M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $11.69M | $3.13M | $731.00K | $379.00K | $52.84M |
| Net Cash Used Provided by Financing Activities | $391.82M | $178.96M | $120.31M | $28.55M | $296.04M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $229.02M | $51.98M | $49.01M | $-34.62M | $258.86M |
| Cash at End of Period | $561.38M | $332.36M | $280.38M | $231.37M | $265.99M |
| Cash at Beginning of Period | $332.36M | $280.38M | $231.37M | $265.99M | $7.13M |
| Operating Cash Flow | $-160.87M | $-124.51M | $-70.06M | $-62.15M | $-36.89M |
| Capital Expenditure | $-1.93M | $-2.46M | $-1.24M | $-1.02M | $-294.00K |
| Free Cash Flow | $-162.80M | $-126.97M | $-71.30M | $-63.17M | $-37.19M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-46.03M | $-52.96M | $-45.26M | $-43.11M | $-40.24M | $-39.44M | $-37.51M | $-35.80M | $-29.72M | $-23.51M | $-27.27M | $-24.19M | $-6.94M | $-20.30M | $-15.62M | $-15.88M | $-10.68M | $-12.04M | $-10.76M | $-11.89M |
| Depreciation and Amortization | $332.00K | $314.00K | $306.00K | $277.00K | $247.00K | $210.00K | $191.00K | $167.00K | $127.00K | $126.00K | $308.00K | $113.00K | $104.00K | $103.00K | $91.00K | $80.00K | $75.00K | $72.00K | $68.00K | $63.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $26.00K | $- | $20.00K | $- | $- | $- | $- | $- |
| Stock Based Compensation | $9.20M | $8.82M | $8.79M | $8.07M | $7.32M | $8.71M | $7.04M | $5.69M | $4.75M | $4.75M | $4.79M | $4.39M | $3.29M | $3.08M | $2.85M | $2.49M | $1.52M | $1.42M | $1.14M | $12.00K |
| Change in Working Capital | $-10.09M | $14.11M | $-3.98M | $-10.13M | $6.88M | $-3.80M | $-913.00K | $-4.81M | $3.08M | $-6.20M | $-632.00K | $18.05M | $-16.96M | $3.26M | $-5.08M | $2.71M | $990.00K | $-365.00K | $-468.00K | $2.12M |
| Accounts Receivables | $-2.35M | $-384.00K | $222.00K | $-83.00K | $-143.00K | $- | $- | $- | $- | $- | $- | $18.00M | $-18.00M | $100.00K | $-100.00K | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $5.85M | $- | $- | $- | $- | $- | $- | $- | $18.00M | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-293.00K | $-1.59M | $1.61M | $23.00K | $1.04M | $-182.00K | $-570.00K | $1.32M | $595.00K | $-4.99M | $4.66M | $-668.00K | $823.00K | $1.44M | $-1.64M | $859.00K | $433.00K | $-3.14M | $2.96M | $-193.00K |
| Other Working Capital | $-7.44M | $16.09M | $-5.82M | $-10.07M | $129.00K | $-3.62M | $-343.00K | $-6.13M | $2.48M | $-1.20M | $-5.29M | $723.00K | $-17.78M | $1.82M | $-3.44M | $1.85M | $557.00K | $2.77M | $-3.42M | $2.31M |
| Other Non Cash Items | $572.00K | $-788.00K | $7.91M | $9.02M | $335.00K | $341.00K | $354.00K | $526.00K | $322.00K | $222.00K | $206.00K | $203.00K | $907.00K | $-589.00K | $103.00K | $99.00K | $98.00K | $49.00K | $91.00K | $1.58M |
| Net Cash Provided by Operating Activities | $-46.01M | $-30.50M | $-39.80M | $-44.56M | $-25.46M | $-33.98M | $-30.83M | $-34.23M | $-21.44M | $-24.60M | $-22.59M | $-1.43M | $-19.57M | $-14.44M | $-17.64M | $-10.51M | $-7.99M | $-10.86M | $-9.93M | $-8.12M |
| Investments in Property Plant and Equipment | $-289.00K | $-386.00K | $-310.00K | $-946.00K | $-541.00K | $-550.00K | $-311.00K | $-1.06M | $-351.00K | $-176.00K | $-567.00K | $-147.00K | $-159.00K | $-145.00K | $-510.00K | $-210.00K | $-60.00K | $-30.00K | $-28.00K | $-176.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-289.00K | $-386.00K | $-310.00K | $-946.00K | $-541.00K | $-550.00K | $-311.00K | $-1.06M | $-351.00K | $-176.00K | $-567.00K | $-147.00K | $-159.00K | $-145.00K | $-510.00K | $-210.00K | $-60.00K | $-30.00K | $-28.00K | $-176.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $73.10M | $155.07M | $629.00K | $151.34M | $68.52M | $284.00K | $1.74M | $107.31M | $61.40M | $48.49M | $9.69M | $118.00K | $28.17M | $35.00K | $57.00K | $42.00K | $140.53M | $- | $- | $56.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.44M | $878.00K | $2.90M | $5.46M | $737.00K | $284.00K | $1.74M | $370.00K | $15.00K | $96.00K | $502.00K | $118.00K | $245.00K | $35.00K | $57.00K | $42.00K | $-413.00K | $9.00K | $100.12M | $55.79M |
| Net Cash Used Provided by Financing Activities | $75.54M | $155.94M | $3.53M | $156.80M | $69.25M | $284.00K | $1.74M | $107.68M | $61.42M | $48.58M | $10.19M | $118.00K | $28.42M | $35.00K | $57.00K | $42.00K | $140.12M | $9.00K | $100.12M | $55.79M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $46.69M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $29.25M | $125.06M | $-36.58M | $111.30M | $43.25M | $-34.25M | $-29.40M | $72.38M | $39.62M | $23.80M | $-12.96M | $-1.46M | $8.69M | $-14.55M | $-18.09M | $-10.67M | $132.07M | $-10.88M | $90.17M | $47.50M |
| Cash at End of Period | $561.38M | $532.13M | $405.86M | $442.44M | $332.36M | $289.11M | $323.35M | $352.76M | $280.38M | $240.75M | $216.95M | $229.91M | $231.37M | $222.68M | $237.23M | $255.32M | $265.99M | $133.93M | $144.80M | $54.63M |
| Cash at Beginning of Period | $532.13M | $407.07M | $442.44M | $331.15M | $289.11M | $323.35M | $352.76M | $280.38M | $240.75M | $216.95M | $229.91M | $231.37M | $222.68M | $237.23M | $255.32M | $265.99M | $133.93M | $144.80M | $54.63M | $7.13M |
| Operating Cash Flow | $-46.01M | $-30.50M | $-39.80M | $-44.56M | $-25.46M | $-33.98M | $-30.83M | $-34.23M | $-21.44M | $-24.60M | $-22.59M | $-1.43M | $-19.57M | $-14.44M | $-17.64M | $-10.51M | $-7.99M | $-10.86M | $-9.93M | $-8.12M |
| Capital Expenditure | $-289.00K | $-386.00K | $-310.00K | $-946.00K | $-541.00K | $-550.00K | $-311.00K | $-1.06M | $-351.00K | $-176.00K | $-567.00K | $-147.00K | $-159.00K | $-145.00K | $-510.00K | $-210.00K | $-60.00K | $-30.00K | $-28.00K | $-176.00K |
| Free Cash Flow | $-46.30M | $-30.89M | $-40.11M | $-45.51M | $-26.00M | $-34.53M | $-31.14M | $-35.30M | $-21.79M | $-24.78M | $-23.16M | $-1.57M | $-19.72M | $-14.59M | $-18.15M | $-10.71M | $-8.05M | $-10.89M | $-9.96M | $-8.30M |
Keros Therapeutics Dividends
Explore Keros Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Keros Therapeutics News
Read the latest news about Keros Therapeutics, including recent articles, headlines, and updates.
Keros Therapeutics Announces Review of Strategic Alternatives
LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors (the “Board”) has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, the Board has authorized the formation of a committee, consisting of independent and disinterested directors, to oversee the process (the “Strategic Committee”) and make a recommendation to the full Board. The Strategic Committee, with the assistance of outside financial and legal advisors, intends to consider a comprehensive range of strategic alternatives, including but not limited to a sale of the company or other business combination transaction, continued investment in the Company's pipeline, and/or return of excess capital to stockholders.
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. Topline results from this ongoing trial are through the multiple ascending dose (“MAD”) treatment period (Day 85).
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade
The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
NEW YORK, NY / ACCESS Newswire / February 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, highlighting preclinical data on its glutocorticoid-induced tumor necrosis factor receptor (GITR) agonist, KROS101. In the talk, titled, “KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Keros Therapeutics, Inc. Being Investigated on Behalf of Keros Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
KROS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Keros Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 10:00 a.m. Eastern time.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Keros Therapeutics, Inc. (KROS)
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, being held February 1-5, 2025 in Maui, Hawaii. The talk, titled, “KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment,” will be held on Febru.
Keros Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - KROS
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for KROS.